MARKET

LUMO

LUMO

Lumos Pharma Inc
NASDAQ
3.100
+0.060
+1.97%
After Hours: 3.100 0 0.00% 16:11 12/04 EST
OPEN
2.960
PREV CLOSE
3.040
HIGH
3.110
LOW
2.960
VOLUME
32.21K
TURNOVER
0
52 WEEK HIGH
5.40
52 WEEK LOW
2.630
MARKET CAP
24.54M
P/E (TTM)
-0.7731
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at LUMO last week (1127-1201)?
Weekly Report · 1d ago
Lumos Pharma Inc: [Amend]General statement of acquisition of beneficial ownership
Press release · 5d ago
Weekly Report: what happened at LUMO last week (1120-1124)?
Weekly Report · 11/27 10:52
Lumos Pharma To Host Virtual Key Opinion Leader Webinar To Discuss Phase 2 OraGrowtH Trial Data And Treatment Potential Of Oral LUM-201 For Pediatric Growth Hormone Deficiency
Lumos pharma, inc. Will host a key opinion leader webinar to discuss topline results from its phase 2 oragrowth210 and ora growt h212 trials in greater detail. Lumos is advancing an oral therapeutic candidate for moderate pediatric growth hormone deficiency.
Benzinga · 11/21 21:29
Weekly Report: what happened at LUMO last week (1113-1117)?
Weekly Report · 11/20 10:50
Lumos Pharma Inc: Current report
Press release · 11/16 00:14
Weekly Report: what happened at LUMO last week (1106-1110)?
Weekly Report · 11/13 10:44
Diageo, Trade Desk, Illumina among premarket losers' pack
Groupon, trade desk, illumina among premarket losers' pack. Plug power plunges 38% on q3 earnings release. Groupon down 29% on earnings release; groupon shares down 2% in premarket trading. Unity software, unity software u and illumina are among the stocks down premarket.
Seeking Alpha · 11/10 13:53
More
About LUMO
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing its clinical program and focused on identifying, acquiring, developing, and commercializing products and new therapies for people with rare diseases. Its pipeline is focused on the development of an orally administered small molecule, LUM-201, which is a growth hormone (GH) secretagogue, also called ibutamoren, for rare endocrine disorders that require injectable recombinant human growth hormone (rhGH). LUM-201 is a tablet formulation that is intended to be administered once daily. LUM-201 stimulates GH via the GH secretagogue receptor (GHSR1a), also known as the ghrelin receptor, and also suppresses the release of somatostatin, thus providing a differentiated mechanism of action to treat some rare endocrine disorders (involving a deficiency of GH) by increasing the amplitude of endogenous, pulsatile GH secretion. Lumos Pharma Sub, Inc. (Private Lumos) is its subsidiary.

Webull offers Lumos Pharma Inc stock information, including NASDAQ: LUMO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LUMO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LUMO stock methods without spending real money on the virtual paper trading platform.